INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,860,253 | +185.1% | 131,700 | +246.6% | 0.05% | +161.1% |
Q2 2023 | $2,406,160 | -11.1% | 38,000 | -24.0% | 0.02% | -25.0% |
Q1 2023 | $2,707,500 | -61.0% | 50,000 | -77.1% | 0.02% | -75.5% |
Q4 2020 | $6,947,000 | -51.3% | 218,473 | -60.7% | 0.10% | -54.8% |
Q3 2020 | $14,275,000 | +107.2% | 556,312 | +107.3% | 0.22% | +108.7% |
Q2 2020 | $6,890,000 | -6.1% | 268,400 | -43.8% | 0.10% | -28.8% |
Q1 2020 | $7,338,000 | -15.3% | 477,426 | -13.0% | 0.15% | +124.6% |
Q3 2017 | $8,663,000 | +332.7% | 548,955 | +997.9% | 0.06% | +182.6% |
Q3 2015 | $2,002,000 | +150.2% | 50,000 | +99.8% | 0.02% | +360.0% |
Q2 2015 | $800,000 | +77.0% | 25,030 | +32.4% | 0.01% | -16.7% |
Q1 2015 | $452,000 | -55.7% | 18,908 | -67.3% | 0.01% | -64.7% |
Q4 2014 | $1,021,000 | +24.1% | 57,853 | -3.6% | 0.02% | 0.0% |
Q3 2014 | $823,000 | -61.1% | 59,995 | -52.2% | 0.02% | -63.8% |
Q2 2014 | $2,116,000 | -40.2% | 125,493 | -35.5% | 0.05% | -51.5% |
Q1 2014 | $3,537,000 | – | 194,563 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |